These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26159375)

  • 1. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
    Signorovitch JE; Betts KA; Song Y; Sorg RA; Li J; Behl AS; Kalsekar A
    J Comp Eff Res; 2015 Nov; 4(6):593-605. PubMed ID: 26159375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
    Suzuki Y; Ikeda K; Suzuki F; Toyota J; Karino Y; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hu W; Eley T; McPhee F; Hughes E; Kumada H
    J Hepatol; 2013 Apr; 58(4):655-62. PubMed ID: 23183526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
    Lu Y; Jin X; Duan CA; Chang F
    PLoS One; 2018; 13(4):e0195117. PubMed ID: 29634736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Takaguchi K; Toyoda H; Tsutsui A; Suzuki Y; Nakamuta M; Imamura M; Senoh T; Nagano T; Tada T; Tachi Y; Hiraoka A; Michitaka K; Shibata H; Joko K; Okubo H; Tsuji K; Takaki S; Watanabe T; Ogawa C; Chayama K; Kumada T; Kudo M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):742-751. PubMed ID: 30848363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
    Lee BS; Song MJ; Kwon JH; Lee TH; Jang JW; Kim SH; Lee SH; Kim HS; Kim JH; Kim SB; Ko SY; Song DS
    Gut Liver; 2019 Mar; 13(2):191-196. PubMed ID: 30400729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
    Sezaki H; Suzuki F; Hosaka T; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Liver Int; 2017 Sep; 37(9):1325-1333. PubMed ID: 28178397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
    Kumada H; Suzuki F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Fujiyama S; Ito T; Itoh Y; Tamura E; Ueki T; Ishikawa H; Hu W; McPhee F; Linaberry M; Hughes E
    J Gastroenterol Hepatol; 2016 Jan; 31(1):14-22. PubMed ID: 26252875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
    Everson GT; Sims KD; Thuluvath PJ; Lawitz E; Hassanein T; Rodriguez-Torres M; Desta T; Hawkins T; Levin JM; Hinestrosa F; Rustgi V; Schwartz H; Younossi Z; Webster L; Gitlin N; Eley T; Huang SP; McPhee F; Grasela DM; Gardiner DF
    Liver Int; 2016 Feb; 36(2):189-97. PubMed ID: 26473667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.
    Wang HL; Lu X; Yang X; Xu N
    J Gastroenterol Hepatol; 2017 Jan; 32(1):45-52. PubMed ID: 27597318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
    Kao JH; Lee YJ; Heo J; Ahn SH; Lim YS; Peng CY; Chang TT; Torbeyns A; Hughes E; Bhore R; Noviello S
    Liver Int; 2016 Oct; 36(10):1433-41. PubMed ID: 27009831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
    Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD
    JAMA; 2015 May; 313(17):1736-44. PubMed ID: 25942724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Hepatol Int; 2016 Mar; 10(2):258-66. PubMed ID: 26542068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
    Liu Y; Wang Z; Tobe RG; Lin H; Wu B
    Clin Drug Investig; 2018 May; 38(5):427-437. PubMed ID: 29417464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
    Nam HC; Lee HL; Yang H; Song MJ
    Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
    Toyoda H; Kumada T; Tada T; Shimada N; Takaguchi K; Senoh T; Tsuji K; Tachi Y; Hiraoka A; Ishikawa T; Shima T; Okanoue T
    J Hepatol; 2017 Mar; 66(3):521-527. PubMed ID: 27890790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
    Miyazaki R; Miyagi K
    Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
    Kao JH; Jensen DM; Manns MP; Jacobson I; Kumada H; Toyota J; Heo J; Yoffe B; Sievert W; Bessone F; Peng CY; Roberts SK; Lee YJ; Bhore R; Mendez P; Hughes E; Noviello S
    Liver Int; 2016 Jul; 36(7):954-62. PubMed ID: 26683763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
    Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
    Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.